Podcast

Freely Filtered 054: EMPA Kidney!

Freely Filtered 054: EMPA Kidney!

Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.

Freely Filtered 052: Acetazolamide for Acute Decompensated Heart Failure (ADVOR)

Freely Filtered 052: Acetazolamide for Acute Decompensated Heart Failure (ADVOR)

Freely Filtered 051: ADVOR turns the practice of sequential nephron blockade on its head by blocking the proximal tubule before the loop of Henle. Does it work? Join The Filtrate as we dissect the latest diuretic RCT.

Freely Filtered 048: Putting TESTING to the Test

Freely Filtered 048: Putting TESTING to the Test

Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with study author Sean Barbour.

Freely Filtered 043: NephMadness and Animal House

Freely Filtered 043: NephMadness and Animal House

Episode 043: Freely Filtered is excited to be the final PodCast of the first NephMadness PodCrawl and we are covering the best region of NephMadness, Animal House! Join us as we discuss the Giraffe versus Whale kidneys and the torpor strategies of the American Black Bear and the Lung Fish.

Freely Filtered 042: Nephrin Antibodies Cause Minimal Change Disease. Wait...What?

Freely Filtered 042: Nephrin Antibodies Cause Minimal Change Disease. Wait...What?

Episode 042: Minimal change disease has classically been described as having negative immunofluorescence and to not be antibody mediated. But here comes Dr Weans with a fresh study smashing this orthodoxy. She proposes anti-nephrin antibodies as the etiologic agent driving minimal change disease.

Freely Filtered 038: AURORA1, a new treatment for Lupus Nephritis

Freely Filtered 038: AURORA1, a new treatment for Lupus Nephritis

Episode 038 Voclosporin is a new calcineurin inhibitors with reliable pharmacokinetics, i.e. no more therapeutic drug monitoring, and it was able to improve complete renal remission in lupus nephritis. But all that glitters is not gold. Join us as we dig deep into the landmark AURORA1 trial.

Freely Filtered 036: AKIKI-2, How soon is now?

Freely Filtered 036: AKIKI-2, How soon is now?

Episode 036 AKIKI-2. Nephrology has been the beneficiary of a handful of studies examining the impact of the timing of the initiation of dialysis in AKI. One of these trials, AKIKI, now has a genuine sequel. In 2016 AKIKI was the first multi-center RCT examining early initiation of dialysis versus late initiation of dialysis and showed that early initiation not only failed to improve patient outcomes but resulted in a significant number of patients receiving dialysis that would have recovered kidney function without intervention had they only been randomized to the late arm. Now five years later we are reviewing the sequel which asks the next logical question, “If delayed dialysis is as good as early dialysis is even later dialysis equivalent or even better?”